The report provides a detailed analysis essential for establishing a urokinase production plant. It encompasses all critical aspects necessary for urokinase production, including the cost of urokinase production, urokinase plant cost, urokinase production costs, and the overall urokinase production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a urokinase production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Urokinase is a naturally occurring enzyme that activates plasminogen. It is a useful drug in the treatment of thromboembolic disease and pulmonary embolism to restore normal blood flow. Moreover, it is used to break down blood clots in patients with conditions such as acute myocardial infarction and deep vein thrombosis. Additionally, it is utilized in protein research to study various physiological and pathological processes and enzyme activity.
The market for urokinase is majorly led by its wide usage for its ability to activate plasminogen and contribute to the treatment of a variety of malignancies, which boosts its market expansion. Moreover, its extensive usage for the treatment of myocardial infarction, acute ischemic stroke, and thrombolytic therapy significantly promotes its demand in the medical and pharmaceutical industries.
Additionally, its application in the biotechnology and research industries to study fibrinolysis, blood clotting, and mechanism of enzyme action to develop new therapeutic agents further enhances its market growth. Furthermore, several factors influence industrial urokinase procurement, such as the source and purity, cost and pricing, compliance with pharmaceutical regulations, quality standards, technological advancements, environmental considerations, sustainability practices, distribution (including trading and shipping), logistics, safety standards, etc.
Raw Material for Urokinase Production
According to the Urokinase production plant project report, the major raw material for Urokinase production includes Human Kidney Cells.
Production Process of Urokinase
The extensive Urokinase production cost report consists of the following industrial production process:
- Production from in vitro Cell Culture: This production process involves the isolation of the urokinase-producing gene from the human kidney cells, followed by its transfer to host cells (mammalian cells). These host cells are cultivated in bioreactors under controlled conditions of temperature, nutrient supply, and pH, which facilitates the production of Urokinase from the cell culture. Additionally, researchers have noticed decreases in urokinase activity in the medium after long-term culture maintenance. However, regularly changing the medium while extracting the enzyme, the cells continue to manufacture the enzyme for a few weeks at a steady pace.
Urokinase is a serine protease that resembles trypsin and is made up of two polypeptide chains joined by a disulfide bond. It constitutes 411 amino acid residues. It can act on both free and bound plasminogen. It is an expensive drug. It is also known as plasminogen activator. It is stable when stored in the form of lyophilized powder under refrigeration 2-8 °C. The molar mass of the compound is 54 kDa. Moreover, it easily dissolves in water and aqueous solutions. It is available as an injection, a straw-colored clear solution known as Kinlytic.
